Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Blood
|
January 17, 2004
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas
Florent Grange, Tony Petrella, Marie Beylot-Barry, et al.
The American Journal of Surgical Pathology
|
January 21, 2014
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients
Fanny Julia, Stephane Dalle, Gerard Duru, et al.
The Lancet. Oncology
|
April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Blood
|
January 26, 2008
Novel markers of normal and neoplastic human plasmacytoid dendritic cells
Teresa Marafioti, Jennifer C Paterson, Erica Ballabio, et al.
Journal of Clinical Pathology
|
October 5, 2006
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
Chalid Assaf, Sylke Gellrich, Sean Whittaker, et al.
The Journal of Investigative Dermatology
|
November 21, 2008
Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type
Nancy J Senff, Willem H Zoutman, Maarten H Vermeer, et al.
American Journal of Clinical Pathology
|
June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review
Tony Petrella, Martine Bagot, Rein Willemze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.
Leukemia & Lymphoma
|
January 19, 2013
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma
Fabrice Jardin, Marie Hélène Delfau-Larue, Thierry Jo Molina, et al.
Blood
|
September 17, 2015
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Blood
|
January 17, 2004
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas
Florent Grange, Tony Petrella, Marie Beylot-Barry, et al.
The American Journal of Surgical Pathology
|
January 21, 2014
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients
Fanny Julia, Stephane Dalle, Gerard Duru, et al.
The Lancet. Oncology
|
April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Blood
|
January 26, 2008
Novel markers of normal and neoplastic human plasmacytoid dendritic cells
Teresa Marafioti, Jennifer C Paterson, Erica Ballabio, et al.
Journal of Clinical Pathology
|
October 5, 2006
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
Chalid Assaf, Sylke Gellrich, Sean Whittaker, et al.
The Journal of Investigative Dermatology
|
November 21, 2008
Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type
Nancy J Senff, Willem H Zoutman, Maarten H Vermeer, et al.
American Journal of Clinical Pathology
|
June 29, 2005
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review
Tony Petrella, Martine Bagot, Rein Willemze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.
Leukemia & Lymphoma
|
January 19, 2013
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma
Fabrice Jardin, Marie Hélène Delfau-Larue, Thierry Jo Molina, et al.
Blood
|
September 17, 2015
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, et al.
Page
of 8